Improved life expectancy of people living with HIV: who is left behind?

dc.contributor.author	Katz, Ingrid
dc.contributor.author	Maughan-Brown, Brendan
dc.date.accessioned	2018-06-14T11:02:39Z
dc.date.available	2018-06-14T11:02:39Z
dc.date.issued	2017-05
dc.identifier.citation	Improved life expectancy of people living with HIV: who is left behind? Katz, Ingrid T et al. The Lancet HIV , Volume 4 , Issue 8 , e324 - e326	en_US
dc.identifier.uri	https://doi.org/10.1016/S2352-3018(17)30086-3
dc.description.abstract	The introduction of combination antiretroviral therapy (ART) has been one of the great public health success stories of the past 40 years. ART has led to increased survival in people living with HIV, and subsequently to individual and societal gains worldwide, because of the marked improvements in its potency, side-effect profile, and simplicity of use.1 Results from the HIV Prevention Trials Network (HPTN) 052 study have clearly proven the efficacy of ART for prevention of transmission,2 while the TEMPRANO and START studies have shown that early ART initiation reduces the risk of serious clinical conditions, the development of AIDS, and death.	en_US
dc.language.iso	en	en_US
dc.publisher	The Lancet	en_US
dc.title	Improved life expectancy of people living with HIV: who is left behind?	en_US
dc.type	Article	en_US

Files in this item

Name: PIIS2352301817300 ...

Size: 474.7Kb

Format: PDF